ABOUT CHRYSALIS BIOTHERAPEUTICS
ChrysalisBioTherapeutics, Inc. is a privately held biopharmaceutical company developing regenerative drugs that mimic the body’s natural signals to activate and protect endothelial progenitor cells and stem cells located within tissues to repair and regenerate tissues damaged by injury, disease, and radiation exposure. Chrysalis BioTherapeutics aims to become a world leader in regenerative medicine by developing safe and effective drugs that stimulate tissue regeneration without isolation and injection of stem cells into damaged tissues. Preclinical and human clinical trial data indicate that this innovative approach has the potential to change the future of regenerative medicine, impact multiple clinical indications, save lives, and improve life’s quality for millions of people.
The company was originally incorporated in 2009 as RADIX Therapeutics. RADIX focused on developing TP508 (Chrysalin® or rusalatide acetate), as a medicinal countermeasure to prevent damaging effects of radiation exposure. RADIX preclinical studies demonstrated that TP508 could be used to mitigate the effects of nuclear radiation when given 24 hours after a potentially lethal exposure. In addition, RADIX preclinical studies demonstrated that TP508 could be used to prevent radiotherapy damage to normal tissue during cancer treatment.
In 2012, RADIX Therapeutics was reincorporated as Chrysalis BioTherapeutics, Inc. and acquired assets from Capstone Therapeutics which included: GMP manufactured TP508 drug product; rights to all proprietary GLP safety, pharmacokinetic, and human clinical trial data; ownership of the FDA IND for use of TP508 in treatment of diabetic foot ulcers; and rights to develop Chrysalin® brand drug products for other clinical indications.
Chrysalis BioTherapeutics has repositioned TP508 as an injectable drug to allow it to be used as a post-exposure radiation countermeasure and a prescriptive drug for treatment of vascular diseases, tissue regeneration, and cancer radiation therapy indications. During this process, the company discovered that the effectiveness of the drug in multiple tissues resulted from effects on endothelial cells and activation of natural progenitor stem cells to repair and regenerate tissues damaged by injury, ischemia, and radiation.